# Micro- and Nanoplastics and Pulmonary Health: The Current State of Research

**Authors:** Charles E. Bardawil, Jarrett Dobbins, Shannon Lankford, Adam C. Soloff, Rajeev Dhupar

PMC · DOI: 10.3390/microplastics5010029 · 2026-03-13

## TL;DR

This paper reviews the effects of micro- and nanoplastics on lung health, highlighting gaps in current research and suggesting ways to improve future studies.

## Contribution

The paper identifies limitations in current exposure studies and proposes standardized, human-relevant models for future research.

## Key findings

- Micro- and nanoplastics can disrupt lung function through oxidative stress and immune activation.
- Most studies use unrealistic plastics and high doses, limiting their clinical relevance.
- Future research should use advanced models and realistic exposure scenarios to improve understanding.

## Abstract

Micro- and nanoplastics are human made environmental contaminants that pose a growing concern for our health, particularly through airborne exposures. Although human autopsy studies confirm that micro- and nanoplastics are retained in lung tissue, our understanding of their short- and long-term effects on the pulmonary system is limited. We reviewed the existing literature to evaluate the effects of micro- and nanoplastics on the respiratory system and how their downstream effects may induce respiratory disease. In vivo and in vitro studies demonstrate that micro- and nanoplastics appear to have the capacity to disrupt pulmonary homeostasis through oxidative stress, immune activation, epithelial remodeling, and surfactant interference. Unfortunately, most available micro- and nanoplastics exposure studies are conducted using environmentally irrelevant plastics at high doses, which limits the accuracy and validity of conclusions regarding biological mechanisms that may contribute to chronic lung disease. To close this gap, future studies must adopt standardized, human-relevant models and realistic exposure scenarios. This includes using advanced in vitro and ex vivo platforms, and environmentally representative micro- and nanoplastics (rather than polystyrene spheres) to improve clinical relevance and support effective prevention and risk mitigation strategies.

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, GLB1 (galactosidase beta 1) [NCBI Gene 2720] {aka EBP, ELNR1, MPS4B}, CXCL6 (C-X-C motif chemokine ligand 6) [NCBI Gene 6372] {aka CKA-3, GCP-2, GCP2, SCYB6}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004] {aka C6orf150, D4, MB21D1, h-cGAS}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, FTH1 (ferritin heavy chain 1) [NCBI Gene 2495] {aka FHC, FTH, FTHL6, HFE5, NBIA9, PIG15}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, TLR2 (toll like receptor 2) [NCBI Gene 7097] {aka CD282, TIL4}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, H3P16 (H3 histone pseudogene 16) [NCBI Gene 644914] {aka H3.6, H3F3AP6, p21}, NOX4 (NADPH oxidase 4) [NCBI Gene 50507] {aka KOX, KOX-1, RENOX}, TIMD4 (T cell immunoglobulin and mucin domain containing 4) [NCBI Gene 91937] {aka SMUCKLER, TIM4}, MIP (major intrinsic protein of lens fiber) [NCBI Gene 4284] {aka AQP0, CTRCT15, LIM1, MIP26, MP26}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, TBK1 (TANK binding kinase 1) [NCBI Gene 29110] {aka AIARV, FTDALS4, IIAE8, NAK, T2K}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, VIM (vimentin) [NCBI Gene 7431], IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, CHEK1 (checkpoint kinase 1) [NCBI Gene 1111] {aka CHK1, OZEMA21}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, MMP12 (matrix metallopeptidase 12) [NCBI Gene 4321] {aka HME, ME, MME, MMP-12}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, IL21 (interleukin 21) [NCBI Gene 59067] {aka CVID11, IL-21, Za11}, TF (transferrin) [NCBI Gene 7018] {aka HEL-S-71p, PRO1557, PRO2086, TFQTL1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}
- **Diseases:** acute lung injury (MESH:D055371), Lung Surfactant Dysfunction (MESH:C580477), cancer (MESH:D009369), tissue damage (MESH:D017695), function (MESH:D003291), Fibrosis (MESH:D005355), alveolar basal epithelial carcinoma (MESH:D009375), Inflammatory (MESH:D007249), Pulmonary Function (OMIM:608852), asthma (MESH:D001249), alveolar epithelial hyperplasia (MESH:D017573), respiratory disease (MESH:D012140), iron overload (MESH:D019190), carcinogenesis (MESH:D063646), asthmatic (MESH:D013224), lung inflammation (MESH:D011014), lung cancer (MESH:D008175), infection (MESH:D007239), injury (MESH:D014947), lung damage (MESH:D008171), Mitochondrial Dysfunction (MESH:D028361), COPD (MESH:D029424), non-small cell lung cancer (MESH:D002289), cytotoxic (MESH:D064420), ALI (MESH:D004618), obstructive and restrictive lung disease (MESH:D008173), lung injury (MESH:D055370)
- **Chemicals:** PVC (MESH:D011143), PFT (MESH:C006717), GSH (MESH:D005978), PET (MESH:D011093), polymethyl methacrylate (MESH:D019904), ROS (MESH:D017382), sodium azide (MESH:D019810), silica (MESH:D012822), water (MESH:D014867), PP (MESH:D011126), ATP (MESH:D000255), methacholine (MESH:D016210), PE (MESH:D020959), Malondialdehyde (MESH:D008315), PS (MESH:D011137), PA (MESH:D011478), rhodamine (MESH:D012235), polymer (MESH:D011108), Micro (-), asbestos (MESH:D001194), nitrite (MESH:D009573), hyaluronan (MESH:D006820), phorbol myristate acetate (MESH:D013755), lipid (MESH:D008055), polyester (MESH:D011091), MDA (MESH:D015104), iron (MESH:D007501), Polyamide (MESH:D009757), Nile Red (MESH:C044808), chlorine (MESH:D002713), MP (MESH:D000080545)
- **Species:** Abelson murine leukemia virus (species) [taxon 11788], Mus musculus (house mouse, species) [taxon 10090], Rodentia (rodent, order) [taxon 9989], Daphnia magna (species) [taxon 35525], Homo sapiens (human, species) [taxon 9606], Nicotiana tabacum (American tobacco, species) [taxon 4097]
- **Cell lines:** A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), RAW 264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493), Calu-3 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0609), BEAS-2B — Homo sapiens (Human), Transformed cell line (CVCL_0168)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12981156/full.md

---
Source: https://tomesphere.com/paper/PMC12981156